MORF SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Investors to Contact the Firm Today!
- NEW YORK, NY / ACCESSWIRE / August 6, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.
- 08/06/2024
|
MORF INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Investors to Contact the Firm Today!
- NEW YORK, NY / ACCESSWIRE / August 5, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.
- 08/05/2024
|
MORF SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Stockholders to Contact the Firm!
- NEW YORK, NY / ACCESSWIRE / August 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.
- 08/04/2024
|
Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
- NEW YORK, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. (“Morphic”) (NASDAQ: MORF) and Eli Lilly and Company (“Eli Lilly”) (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.
- 08/02/2024
|
MORF INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Stockholders to Contact the Firm!
- NEW YORK, NY / ACCESSWIRE / August 2, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.
- 08/02/2024
|
MORF STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Shareholders to Contact the Firm!
- NEW YORK, NY / ACCESSWIRE / August 1, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.
- 08/01/2024
|
MORF SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Shareholders to Contact the Firm!
- NEW YORK, NY / ACCESSWIRE / July 31, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.
- 07/31/2024
|
MORF Alert: Wohl & Fruchter LLP Files Class Action Lawsuit on Behalf of Shareholders of Morphic Holding, Inc., in the U.S. District Court for the Northern District of California
- MONSEY, N.Y., July 31, 2024 (GLOBE NEWSWIRE) -- Wohl & Fruchter LLP announces that on July 25, 2024, it filed a class action lawsuit in the United States District Court for the Northern District of California, captioned Zappia v.
- 07/31/2024
|
MORF INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Shareholders to Contact the Firm!
- NEW YORK, NY / ACCESSWIRE / July 30, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.
- 07/30/2024
|
Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
- NEW YORK--(BUSINESS WIRE)---- $MORF #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. (“Morphic”) (NASDAQ: MORF) and Eli Lilly and Company (“Eli Lilly”) (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF. Investigation Details The investigation concerns whether Morphic's board of direct.
- 07/29/2024
|
MORF STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Investors to Contact the Firm!
- NEW YORK, NY / ACCESSWIRE / July 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.
- 07/29/2024
|
Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
- NEW YORK, July 28, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. (“Morphic”) (NASDAQ: MORF) and Eli Lilly and Company (“Eli Lilly”) (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.
- 07/28/2024
|
MORF SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Investors to Contact the Firm!
- NEW YORK, NY / ACCESSWIRE / July 28, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.
- 07/28/2024
|
MORF INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Investors to Contact the Firm!
- NEW YORK, NY / ACCESSWIRE / July 26, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.
- 07/26/2024
|
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Morphic Holding, Inc. - MORF
- NEW YORK , July 23, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Morphic Holding, Inc. (Nasdaq: MORF ), relating to its proposed merger with Eli Lilly and Company.
- 07/23/2024
|
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHCR, MORF on Behalf of Shareholders
- NEW YORK, July 20, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
- 07/20/2024
|
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Morphic Holding, Inc. – MORF
- NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Morphic Holding, Inc . ( Nasdaq : MORF ), relating to its proposed merger with Eli Lilly and Company. Under the terms of the agreement, Morphic Holding shareholders will receive $57.00 in cash per share they own.
- 07/19/2024
|
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SPR, MORF on Behalf of Shareholders
- NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
- 07/11/2024
|
MORPHIC HOLDING INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Morphic Holding, Inc. - MORF
- NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Morphic Holding, Inc. (NasdaqGM: MORF) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of Morphic will receive $57.00 in cash for each share of Morphic that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequa.
- 07/09/2024
|
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MORF, DM on Behalf of Shareholders
- NEW YORK , July 9, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Morphic Holding, Inc. (NASDAQ: MORF)'s sale to Eli Lilly and Company for $57.00 per share in cash. If you are a Morphic shareholder, click here to learn more about your rights and options.
- 07/09/2024
|
PARA/Skydance Agreement, LLY to Acquire MORF, NOW Downgrade
- Paramount (PARA) enters a definitive merger agreement with Skydance Media. Eli Lilly (LLY) is acquiring Morphic Therapeutics (MORF) for $3.2B cash.
- 07/08/2024
|
Eli Lilly to acquire Morphic in $3.2B deal
- Pharmaceutical giant Eli Lilly (LLY) has reached an agreement to purchase biopharmaceutical company Morphic (MORF) in a deal valued at $3.2 billion. This strategic move marks a notable expansion in Eli Lilly's portfolio and research capabilities.
- 07/08/2024
|
Why Is Morphic (MORF) Stock Up 75% Today?
- Morphic (NASDAQ: MORF ) stock is rocketing higher on Monday after the company reached an acquisition agreement with Eli Lilly (NYSE: LLY ). With this agreement, Eli Lilly will acquire Morphic for $3.2 billion in cash.
- 07/08/2024
|
Eli Lilly Buys Morphic for $3.2B
- Eli Lilly (LLY) agreed to buy biopharmaceutical firm Morphic (MORF) at a significant premium, sending shares of Morphic skyrocketing Monday.
- 07/08/2024
|
Eli Lilly Buys Bowel Disease Drug Developer Morphic In $3.2 Billion Deal
- Eli Lilly will acquire biopharmaceutical firm Morphic Holding in a deal valued at $3.2 billion, both companies announced Monday, a transaction that includes an experimental medication for inflammatory bowel disease and treatments for other chronic diseases.
- 07/08/2024
|
MORF Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Morphic Holding to Eli Lilly
- MONSEY, N.Y., July 08, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Morphic Holding, Inc. (Nasdaq: MORF) (“Morphic”) to Eli Lilly and Company (“Eli Lilly”) for $57.00 per share in cash in a tender offer.
- 07/08/2024
|
Nasdaq Index, Dow Jones, S&P 500 News: Morphic Holding Shares Surge Over 75%; Alibaba Group Stumbles
- Nasdaq flat, but Alibaba shares dip 1.17% pre-market as AI progress showcased at Shanghai conference.
- 07/08/2024
|
Eli Lilly's First Biotech Deal Of 2024, Buys Chronic Disease Player Morphic For $3.2B
- Monday, Eli Lilly And Co LLY agreed to acquire Morphic Holding Inc MORF for $57 per share in cash, an aggregate of approximately $3.2 billion.
- 07/08/2024
|
Eli Lilly to acquire Morphic Therapeutics for $3.2 billion in cash
- CNBC's Joe Kernen reports on the latest news.
- 07/08/2024
|
Eli Lilly to Buy Morphic for $3.2 Billion. Morphic Stock Surges 78%.
- Eli Lilly agrees to pay $57 a share for Morphic, or a 79% premium to the stock's closing price of $31.84 on Friday.
- 07/08/2024
|
Morphic's stock rockets after $3.2 billion buyout deal with Eli Lilly
- Shares of Morphic Holding Inc. MORF, +0.03% rocketed 76% in premarket trading Monday, after the biopharmaceutical company announced an agreement to be acquired by Eli Lilly & Co. LLY, +1.83% in a cash deal valued at about $3.2 billion. Lilly's stock LLY, +1.83% tacked on 0.2% ahead of the open.
- 07/08/2024
|
Eli Lilly to acquire Morphic Holding for $3.2 billion
- Eli Lilly will acquire Morphic Holding for $3.2 billion, the companies said on Monday.
- 07/08/2024
|
Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease
- Acquisition to expand Lilly's immunology pipeline with oral integrin therapies INDIANAPOLIS and WALTHAM, Mass. , July 8, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Morphic Holding, Inc. (NASDAQ: MORF) today announced a definitive agreement for Lilly to acquire Morphic, a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases.
- 07/08/2024
|
MORF NEWS: Johnson Fistel Continues Investigation on Behalf of Morphic Holding Shareholders
- SAN DIEGO, CA / ACCESSWIRE / June 17, 2024 / Johnson Fistel, is investigating potential securities claims against Morphic Holding, Inc. (NASDAQ:MORF) on behalf of stockholders. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.
- 06/17/2024
|
Morphic to Participate in Jefferies Global Healthcare Conference
- WALTHAM, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of its management team will take part in a fireside chat at the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5th, at 10:30 AM ET.
- 05/31/2024
|
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024
- MORF ends 1Q24 with $659 million, cash into 2H27; phase 2b study of MORF-057 in UC continues on target; anticipate GARNET phase 2 in Crohn's to begin 2Q
- 04/25/2024
|
What Makes Morphic (MORF) a New Buy Stock
- Morphic (MORF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 04/24/2024
|
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / April 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 04/16/2024
|
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / April 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 04/15/2024
|
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / April 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 04/11/2024
|
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / April 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 04/05/2024
|
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / April 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 04/04/2024
|
Ademi LLP Investigates Claims of Securities Fraud against Morphic Holding, Inc.
- MILWAUKEE , April 2, 2024 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Morphic (NASDAQ: MORF). The investigation results from inaccurate statements Morphic may have made regarding its business operations and prospects.
- 04/02/2024
|
Morphic Holding, Inc. (MORF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
- NEW YORK--(BUSINESS WIRE)---- $MORF #classaction--Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Morphic Holding, Inc. (“Morphic” or “the Company”) (NASDAQ: MORF). Investors who purchased Morphic securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/morf. The investigation concerns whether Morphic has violated federal securities laws. Investigation Details: On September.
- 04/02/2024
|
Morphic Holding, Inc. (MORF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
- NEW YORK--(BUSINESS WIRE)---- $MORF #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Morphic Holding, Inc. (“Morphic” or “the Company”) (NASDAQ: MORF). Investors who purchased Morphic securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/morf. The investigation concerns whether Morphic has violated federal securities laws. Investigation Details: On September.
- 03/26/2024
|
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / March 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 03/26/2024
|
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / March 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 03/22/2024
|
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / March 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 03/20/2024
|
Morphic Appoints Dr. Simon Cooper as Chief Medical Officer
- Experienced Clinical Development Leader with Deep Experience in Immunology and Inflammatory Diseases Experienced Clinical Development Leader with Deep Experience in Immunology and Inflammatory Diseases
- 03/19/2024
|
Morphic to Participate in March Investor Conferences
- WALTHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced its participation at investor conferences during the month of March.
- 03/05/2024
|
Wall Street Analysts See a 56.18% Upside in Morphic Holding, Inc. (MORF): Can the Stock Really Move This High?
- The average of price targets set by Wall Street analysts indicates a potential upside of 56.2% in Morphic Holding, Inc. (MORF). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 02/26/2024
|
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2023
- MORF ends '23 with $700 million, cash into 2H27; MORF-057 EMERALD-2 UC trial enrolling on target; to begin Ph 2 GARNET trial of 057 in Crohn's disease 1H24
- 02/22/2024
|
Best Momentum Stocks to Buy for February 14th
- LUMN, SFST and MORF made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 14, 2023.
- 02/14/2024
|
New Strong Buy Stocks for February 14th
- GLTO, LUMN, MORF, SFST and STOK have been added to the Zacks Rank #1 (Strong Buy) List on February 14, 2023.
- 02/14/2024
|
Wall Street Analysts Think Morphic Holding, Inc. (MORF) Could Surge 57.22%: Read This Before Placing a Bet
- The consensus price target hints at a 57.2% upside potential for Morphic Holding, Inc. (MORF). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 02/08/2024
|
Wall Street Analysts Believe Morphic Holding, Inc. (MORF) Could Rally 110.28%: Here's is How to Trade
- The mean of analysts' price targets for Morphic Holding, Inc. (MORF) points to an 110.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 01/05/2024
|
Morphic to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- -Dr. Praveen Tipirneni, returns in full capacity as Chief Executive Officer from medical leave- WALTHAM, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D.
- 01/03/2024
|
Does Morphic Holding, Inc. (MORF) Have the Potential to Rally 92.88% as Wall Street Analysts Expect?
- The average of price targets set by Wall Street analysts indicates a potential upside of 92.9% in Morphic Holding, Inc. (MORF). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 12/20/2023
|
Wall Street Analysts See a 150.17% Upside in Morphic Holding, Inc. (MORF): Can the Stock Really Move This High?
- The mean of analysts' price targets for Morphic Holding, Inc. (MORF) points to a 150.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 12/01/2023
|
Morphic Holding, Inc. (MORF) Moves to Buy: Rationale Behind the Upgrade
- Morphic Holding, Inc. (MORF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 11/09/2023
|
Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set
- WALTHAM, Mass., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced it will host a webcast and conference call to discuss the complete results from the open-label EMERALD-1 Phase 2a study of MORF-057 in adults with moderate to severe ulcerative colitis. The positive topline results from EMERALD-1 were reported in April of this year and the full data set will be presented at the upcoming UEG Week 2023.
- 10/09/2023
|
Morphic Holding: The Price Drop Is Very Interesting
- Morphic Holding, Inc.'s stock has dropped 61% in just 2 months, calling into question its $3bn valuation. The company's lead asset, MORF-057, targets the integrin α4β7, but faces tough competition from the biologic drug Vedolizumab. Updated data from the EMERALD-1 trial showed lower rates of endoscopic improvement compared to Vedolizumab, causing the stock to plummet.
- 09/28/2023
|
Morphic to Present Positive EMERALD-1 Phase 2a Data for MORF-057 in Patients with Moderate to Severe Ulcerative Colitis in Abstract for UEGW 2023
- -Orally administered MORF-057 achieved primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures-
- 09/22/2023
|
Morphic Holding, Inc. (MORF) Reports Q2 Loss, Lags Revenue Estimates
- Morphic Holding, Inc. (MORF) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to earnings of $0.68 per share a year ago.
- 08/03/2023
|
Morphic: High Valuation Not Justified By Data, Development Status, Or Cash
- Morphic Holding, Inc. is progressing with its trials nicely enough. I just have a problem with the nearly $3bn valuation for this phase 2 stage company. Nothing they have done or said justifies it.
- 07/10/2023
|
3 Stocks That Could Skyrocket by This Time Next Summer
- I'm searching for the best stocks to skyrocket by this time next summer. A quick screen of U.S.-listed stocks tells me there are 51 that doubled or better over the past year out of 1,904 companies with market capitalizations of $2 billion or greater.
- 06/08/2023
|
Morphic to Present at the Jefferies Global Healthcare Conference
- WALTHAM, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate in the Jefferies Healthcare Conference, including a hosted fireside chat, on Wednesday, June 7, 2023.
- 06/06/2023
|
Morphic to Present at 2023 RBC Capital Markets Global Healthcare Conference
- WALTHAM, Mass., May 12, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate in a Fireside Chat at the 2023 RBC Capital Markets Global Healthcare Conference on Wednesday, May 17, 2023.
- 05/12/2023
|
3 Biotech Buyout Targets to Watch
- 89bio's stock is up more than 21% this year. Karuna Therapeutics says it plans to file an NDA for its lead therapy this year.
- 04/29/2023
|
Morphic: Positive Phase 2a UC Trial, Top M&A Candidate In 2023
- Morphic: Positive Phase 2a UC Trial, Top M&A Candidate In 2023.
- 04/25/2023
|
Morphic Holding, Inc. (MORF) Reports Q1 Loss, Lags Revenue Estimates
- Morphic Holding, Inc. (MORF) came out with a quarterly loss of $0.90 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.85 per share a year ago.
- 04/25/2023
|
Morphic Holding, Inc. (MORF) Moves 22.5% Higher: Will This Strength Last?
- Morphic Holding, Inc. (MORF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
- 04/18/2023
|
7 Biotech Stocks to Buy for 100% Returns
- Generally speaking, biotech stocks to buy offer investors an excellent opportunity for significant upside success. According to Grand View Research, the global market size for the industry reached $1.02 trillion in 2021.
- 04/09/2023
|
Morphic to Present at TD Cowen 43rd Annual Health Care Conference
- WALTHAM, Mass., March 03, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate a panel discussion focused on new approached to treat gastroenterological diseases and a corporate fireside chat at the TD Cowen 43rd Annual Health Care Conference.
- 03/03/2023
|
Morphic to Present at SVB Leerink Global Healthcare Conference
- WALTHAM, Mass., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate in the virtual SVB Leerink Global Healthcare conference including a hosted fireside chat.
- 02/14/2023
|
Morphic Holding: Technical Case For Tactical Medium-Term Buy (Technical Analysis)
- Morphic Holding has curled up off recent lows and caught a strong bid into the new year. It broke out above its longer-term resistance level and has finished above this mark for the last 3-weeks of trade.
- 02/07/2023
|
Morphic Holding, Inc. (MORF) Surges 18.7%: Is This an Indication of Further Gains?
- Morphic Holding, Inc. (MORF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 01/13/2023
|
Morphic to Present at the 41st Annual J.P. Morgan Healthcare Conference
- WALTHAM, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 2:15 PM PST.
- 01/05/2023
|
Morphic Holding, Inc. (MORF) Moves 7.3% Higher: Will This Strength Last?
- Morphic Holding, Inc. (MORF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 09/29/2022
|
Strength Seen in Morphic Holding, Inc. (MORF): Can Its 7% Jump Turn into More Strength?
- Morphic Holding, Inc. (MORF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 04/27/2022
|
Morphic Holding, Inc. (MORF) Upgraded to Buy: What Does It Mean for the Stock?
- Morphic Holding, Inc. (MORF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 01/05/2022
|
Morphic: Pioneering Integrin Medicines
- Morphic is pursuing a multi-billion opportunity of replacing biologics modulating integrins with small molecules. The company is founded by the individual who discovered integrins and has built a unique technology platform to design selective oral therapies for integrins.
- 10/13/2021
|
New Strong Sell Stocks for September 16th
- CLMT, FANH, and MORF have been added to the Zacks Rank #5 (Strong Sell) List on September 16, 2021.
- 09/16/2021
|
Morphic Therapeutic Announces Appointment of Nisha Nanda, Ph.D., to Board of Directors
- WALTHAM, Mass., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the appointment of Nisha Nanda, Ph.D., to its Board of Directors. Dr. Nanda currently serves as the chief development officer for Loxo Oncology at Lilly.
- 08/23/2021
|
Morphic Holding, Inc. (MORF) Reports Q2 Loss, Misses Revenue Estimates
- Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of -40.00% and -35.87%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/04/2021
|
Morphic Therapeutic Shares New Positive MORF-057 Data From IBD Study
- Morphic Therapeutic (NASDAQ: MORF) has announced additional data from its Phase 1 trial evaluating MORF-057 for inflammatory bowel disease (IBD). The data were shared at the Congress of European Crohn's and Colitis Organization 2021 Virtual Congress.
- 07/09/2021
|
Morphic Reports New Data from Positive Phase 1 Study of MORF-057, Oral Integrin Inhibitor Candidate for IBD
- MORF-057 well tolerated across all phase 1 cohorts
- 07/09/2021
|
Strength Seen in Morphic Holding, Inc. (MORF): Can Its 6% Jump Turn into More Strength?
- Morphic Holding, Inc. (MORF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
- 06/03/2021
|
Morphic Therapeutic to Present Positive Phase 1 Data for MORF-057 at ECCO'21 Virtual Congress
- Presentation will include summary safety, pharmacokinetic and pharmacodynamic data from single ascending dose (SAD), food effect and multiple ascending dose (MAD) studies
- 05/28/2021
|
Morphic Therapeutic to Present at the Jefferies Virtual Healthcare Conference
- WALTHAM, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of the Morphic leadership team are scheduled to present at the Jefferies Virtual Healthcare Conference on June 4, 2021 at 9:00 AM ET.
- 05/28/2021
|
Morphic Announces Corporate Highlights and First Quarter 2021 Financial Results
- Expanded research and development collaboration with Janssen for third integrin program
- 04/29/2021
|
Morphic Therapeutic Announces Appointment of Susannah Gray as Member of its Board of Directors
- Otello Stampacchia steps down, Vikas Goyal to leave Morphic Board at the end of current term Otello Stampacchia steps down, Vikas Goyal to leave Morphic Board at the end of current term
- 04/28/2021
|
Is Morphic Holding a Buy?
- This experimental biotech has more than tripled investors' money over the past 12 months.
- 04/14/2021
|
MORF Stock Price: $103 Target (Up From $40) By Wells Fargo
- The shares of Morphic Holding Inc (NASDAQ: MORF) have received a price target increase from $40 to $103 by Wells Fargo. These are the details.
- 03/07/2021
|
Morphic Therapeutic Announces Pricing of Upsized $245.0 Million Public Offering
- WALTHAM, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the pricing of an upsized underwritten public offering of 3,500,000 shares of its common stock at a price to the public of $70.00 per share. The gross proceeds from this offering are expected to be approximately $245.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Morphic. The offering is expected to close on or about March 5, 2021, subject to the satisfaction of customary closing conditions. Morphic has also granted the underwriters a 30-day option to purchase up to an additional 525,000 shares of common stock in connection with the public offering. All of the shares of common stock are being offered by Morphic.
- 03/02/2021
|
Why Morphic Holding Stock Is Falling Today
- The company announced a proposed public offering of common stock.
- 03/02/2021
|
Morphic Therapeutic Announces Proposed Public Offering
- WALTHAM, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced a proposed underwritten public offering in which it intends to offer and sell $200.0 million of shares of its common stock. In addition, Morphic intends to grant the underwriters a 30-day option to purchase up to an additional $30.0 million of shares of its common stock. All of the shares of common stock are being offered by Morphic. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- 03/01/2021
|
Morphic Holding, Inc. (MORF) CEO Praveen Tipirneni on Q4 2020 Results - Earnings Call Transcript
- Morphic Holding, Inc. (MORF) CEO Praveen Tipirneni on Q4 2020 Results - Earnings Call Transcript
- 03/01/2021
|
Why Morphic Holding Stock Is Skyrocketing Today
- A series of positive news is helping the biopharmaceutical company start the week on a strong note.
- 03/01/2021
|
Why Morphic, Athenex, Lixte Biotech Are Moving Today
- Morphic Holding Inc (NASDAQ: MORF), Athenex Inc (NASDAQ: ATNX) and Lixte Biotechnology Holdings Inc (NASDAQ: LIXT) are among the healthcare movers on Monday. Morphic Jumps On Data: Morphic, a biopharma developing oral integrin therapies for treating chronic diseases, reported positive Phase 1 data for its MORF-057, which is being evaluated for inflammatory bowel disease.
- 03/01/2021
|
MORF Stock: Why Little-Known Morphic Holdings Is Up 100% Today
- Little-known MORF stock is rocketing higher after Morphic Holdings shared positive interim data from a Phase 1 clinical trial. The post MORF Stock: Why Little-Known Morphic Holdings Is Up 100% Today appeared first on InvestorPlace.
- 03/01/2021
|
MORF Stock Price Increases Over 100% Intraday: Why It Happened
- The stock price of Morphic Holding Inc (NASDAQ: MORF) has increased by over 100% during intraday trading as of 11 AM ET. This is why it happened.
- 03/01/2021
|
Morphic Holding, Inc. (MORF) Reports Q4 Loss, Misses Revenue Estimates
- Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of -54.05% and -26.24%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 03/01/2021
|
Morphic Reports Positive Interim Results from Single Ascending Dose Phase 1 Clinical Trial of MORF-057
- MORF-057 well tolerated in all dose cohorts
- 03/01/2021
|
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2020
- Announced positive preliminary results from Phase 1 SAD clinical trial of MORF-057
- 03/01/2021
|
Morphic Therapeutic to Participate in GI/Microbiome Panel Discussion at the 41st Annual Cowen Health Care Conference
- WALTHAM, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., president and chief executive officer of Morphic Therapeutic, is scheduled to participate in a panel discussion on the gastrointestinal microbiome at the 41st Annual Cowen Health Care Conference. The panel discussion will take place at 11:10 AM ET on Tuesday, March 2, 2021.
- 02/16/2021
|
Morphic Expands Research and Development Collaboration with Janssen Through Third Integrin Program
- New program demonstrates breadth of MInT platform with the inclusion of activating antibodies against integrin targets New program demonstrates breadth of MInT platform with the inclusion of activating antibodies against integrin targets
- 01/05/2021
|
Analyst talks Biotech sector, offers three picks for 2021
- The biotechnology exchange-traded fund SPDR S&P Biotech ETF (NYSE: XBI) is up around 50% in 2020 and Jefferies' managing director Michael Yee says the valuations are not only justified but sustainable in 2021. ‘Exciting stories' for 2021 While looking at the Biotech sector, it is important to separate the small group of COVID-19 vaccine makers from the overall biotech innovation thesis, Yee said Tuesday on CNBC's “Closing Bell.
- 12/30/2020
|
Morphic Therapeutic to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
- WALTHAM, Mass., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced that Praveen Tipirneni, M.D., president and chief executive officer, will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 4:30 PM ET.
- 12/30/2020
|
Morphic Holding's (MORF) Shares March Higher, Can It Continue?
- As of late, it has definitely been a great time to be an investor in Morphic Holding (MORF).
- 12/15/2020
|
Morphic Therapeutic to Present at the Jefferies Virtual London Healthcare Conference
- WALTHAM, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that members of the Morphic management are scheduled to participate in the Jefferies Virtual London Healthcare Conference with a Company presentation at 2:55 PM ET on Wednesday, November 18, 2020.
- 11/17/2020
|
Morphic Announces Corporate Highlights and Third Quarter 2020 Financial Results
- Initiated p hase 1 clinical trial for MORF-057 with results expected by mid-2021
- 11/09/2020
|
Morphic Holding, Inc. (MORF) Reports Q2 Loss, Tops Revenue Estimates
- Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of 13.33% and 37.38%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 08/10/2020
|
Morphic Announces Corporate Highlights and Second Quarter 2020 Financial Results
- Company’s first IND accepted by FDA for MORF-057 in IBD Phase 1 study expected to begin in third-quarter 2020 Positive data presented at DDW 2020 further support MORF-057 preclinical profile WALTHAM, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and second quarter 2020 financial results.“Morphic has made tremendous strides with our lead program, MORF-057, an oral small molecule inhibitor of α4β7 in development to treat inflammatory bowel disease. I’m so proud of the efforts of our team that has taken this program from the bench in Dr. Tim Springer’s Lab to the clinic in just a few short years,” commented Praveen Tipirneni, M.D., president and chief executive officer of Morphic Therapeutic. “We recently presented a substantive preclinical data set at Digestive Disease Week that support MORF-057’s profile as a candidate for the treatment of IBD through the proven mechanism of α4β7 inhibition with many potential advantages, including oral administration. While we are just beginning our clinical journey, I congratulate the Morphic team for the achievement of these important milestones on our mission to deliver a new generation of oral integrin therapeutics.”Peter Linde, M.D., Morphic’s chief medical officer, added, “We expect to initiate a robust clinical development program for MORF-057 imminently, beginning with a phase 1 clinical trial designed to evaluate the safety, pharmacokinetic and pharmacodynamic profile of this compound with single and multiple ascending dose cohorts. The phase 1 trial will also generate important receptor occupancy data that we believe could provide early clinical proof of concept and dose selection guidance for use in future studies within the MORF-057 program in IBD patients.”Morphic is developing MORF-057 as a selective, oral small molecule inhibitor of the α4β7 integrin, a target for the treatment of inflammatory bowel disease (IBD) with an initial focus on moderate-to-severe ulcerative colitis (UC). The mechanism of α4β7 inhibition to treat IBD has been clinically validated by the success of the approved infused antibody therapy, vedolizumab.Second quarter and recent corporate highlights: * Announced acceptance of the Investigational New Drug (IND) filing for MORF-057 by the U.S. Food and Drug Administration (FDA), with a phase 1 clinical trial in healthy subjects expected to begin in the third quarter of 2020 * The phase 1 trial is a randomized, double-blind placebo-controlled single and multiple ascending dose study in healthy adults evaluating endpoints including safety, tolerability, and pharmacokinetic and pharmacodynamic measures, as well as a concurrent food effect study * The full data set from the MORF-057 phase 1 trial is expected to be presented by mid-2021 * Presented new positive preclinical data supporting MORF-057 in models of increasing complexity at the virtual Digestive Disease Week 2020 * These data demonstrated MORF-057’s inhibition of α4β7 -expressing lymphocyte migration to the gut, a fundamental contributor to IBD, acting through the same mechanism of action as the approved antibody therapeutic, vedolizumab * Further, oral administration of a MORF-057 analog in non-human primate studies demonstrated saturation of the α4β7 receptor throughout the entire 7-day dosing period – receptor saturation at the dosages assessed in preclinical studies provide further evidence that MORF-057 is an extremely potent inhibitor of α4β7 and may produce clinical efficacy * Continued progress in our collaboration with AbbVie on the development of integrin inhibitors, including αvβ6 and other integrin targets * Appointed Marc Schegerin, M.D., MBA, as chief operating officer and chief financial officer; Dr. Schegerin was previously chief financial officer of ArQule until its acquisition by Merck. His prior roles include senior positions in finance, business development and healthcare investment bankingCOVID-19 Preparedness Morphic is not currently aware of any significant delay to its timelines due to the COVID-19 pandemic. In light of the evolving circumstances, Morphic will continue to assess any potential impact of the COVID-19 pandemic in dialogue with regulators, partners and vendors.Financial Results for Second Quarter 2020Net loss for the quarter ended June 30, 2020 was $15.9 million or $0.52 per share compared to a net loss of $9.4 million or $4.73 per share for the same quarter last year. * Revenue was $7.7 million for the quarter ended June 30, 2020 compared to $5.6 million for the same quarter last year. The increase was due to higher level of research & development efforts in collaboration agreements signed with AbbVie in October 2018 and Janssen in February 2019 * Research and development expenses were $19.9 million for the quarter ended June 30, 2020, compared to $13.9 million in the same quarter last year. The $6.0 million increase year-over-year reflects development and manufacturing costs associated with lead wholly owned product candidate, MORF-057; research costs associated with preclinical studies related to our partnered product candidate MORF-720 with AbbVie; as well as increased personnel-related costs to support continued progress with the company’s pipeline * General and administrative expenses were $4.2 million for the quarter ended June 30, 2020, compared to $2.1 million in the same quarter last year. The $2.1 million increase year-over-year was primarily attributable to increased headcount and higher professional fees to operate as a public company along with consulting fees associated with ongoing business development activitiesAs of June 30, 2020, Morphic had cash, cash equivalents and marketable securities of $202.5 million, compared to $237.0 million at the end of 2019. Morphic believes its cash, cash equivalents and marketable securities balance as of June 30, 2020 will be sufficient to fund operating expenses and capital expenditure requirements at least through the end of 2022.Financial Tables Follow Morphic Holding Inc. Condensed Consolidated Statements of Operations (unaudited) (in thousands, except share and per share data) Three Months Ended Six Months Ended June 30 June 30 2020 2019 2020 2019 Collaboration revenue$7,693 $ 5,567 $13,287 $ 11,635 Operating expenses: Research and development 19,918 13,907 38,878 24,278 General and administrative 4,195 2,077 8,618 3,908 Total operating expenses 24,113 15,984 47,496 28,186 Loss from operations (16,420) (10,417) (34,209) (16,551) Interest income, net 407 1,119 1,293 2,182 Total other income 407 1,119 1,293 2,182 Loss before benefit from (provision for) income taxes (16,013) (9,298) (32,916) (14,369) Benefit from (provision for) income taxes 155 (135) 312 (264) Net loss$(15,858) $(9,433) $(32,604) $(14,633) Net loss per share, basic and diluted$(0.52) $(4.73) $1.08 $(7.54) Weighted-average common shares outstanding, basic and diluted 30,360,851 1,992,410 30,274,713 1,940,923 Morphic Holding Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands) June 30, 2020 December 31, 2019 Assets Cash, cash equivalents and marketable securities$202,538 $237,016 Other current assets 6,072 6,557 Total current assets 208,610 243,573 Other assets 3,389 3,862 Total assets$211,999 $247,435 Liabilities and Stockholders' Equity Current liabilities$45,284 $35,350 Long-term liabilities 51,798 71,167 Total liabilities 97,082 106,517 Total stockholders' equity 114,917 140,918 Total liabilities and stockholders' equity$211,999 $247,435 About Morphic Therapeutic Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. In collaboration with AbbVie, Janssen and Schrödinger, Morphic is advancing its pipeline and discovery activities using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.Cautionary Note Regarding Forward-Looking Statements This press release contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: Morphic’s plan to develop and commercialize oral small-molecule integrin therapeutics and Morphic’s expectations about timing and ability to commence or complete clinical studies and to obtain regulatory approvals for MORF-057, MORF-720, and other candidates in development, the ability of MORF-057 to treat inflammatory bowel disease, the potential impact of the COVID-19 pandemic and the sufficiency of our cash, cash equivalents and investments to fund our operations. Statements including words such as “believe,” “plan,” “continue,” “expect,” “will be,” “develop,” “signal,” “potential,” or “ongoing” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements.
- 08/10/2020
|
Schrödinger, Inc. Reports Second Quarter 2020 Financial Results and Business Updates
- Schrödinger today announced financial results for the second quarter ended June 30, 2020.
- 08/10/2020
|
Morphic Holding's (NASDAQ:MORF) Stock Price Has Reduced13% In The Past Year
- It is a pleasure to report that the Morphic Holding, Inc. (NASDAQ:MORF) is up 58% in the last quarter. But that...
- 08/07/2020
|
Morphic Holding, Inc. (MORF) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
- Morphic Holding, Inc. (MORF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 08/03/2020
|
Morphic Therapeutic Presents Positive Preclinical Data Supporting Development of MORF-057 in Inflammatory Bowel Disease at Digestive Disease Week 2020
- Receptor occupancy, potency and selectivity data further build MORF-057 preclinical profile as an oral small molecule treatment candidate for IBD IND filing on track for.
- 06/29/2020
|
Morphic Holding (MORF) Investor Presentation - Slideshow
|
Morphic to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference
- Morphic Therapeutic (MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., president and chief executive officer, and Marc Schegerin, M.D., chief financial officer and chief operating officer, are scheduled to make a presentation at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference at 11:00 a.m. ET on Tuesday, June 23, 2020. Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer.
- 06/18/2020
|
Hedge Funds Nibbling On Morphic Holding, Inc. (MORF)
- At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each […]
- 06/16/2020
|
Morphic to Present at the Jefferies Virtual Healthcare Conference
- Morphic Therapeutic (MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that the Morphic executive team is scheduled to make a presentation at the Jefferies Virtual Healthcare Conference at 2:30 p.m. ET on Wednesday, June 3, 2020. Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer.
- 05/27/2020
|
Morphic Announces Corporate Highlights and First Quarter 2020 Financial Results
- Data presented at ECCO Congress support MORF-057 in IBD; IND on track for mid-year Recent executive appointments of Peter Linde, M.D., as CMO and Marc Schegerin, M.D., as.
- 05/06/2020
|
Morphic Therapeutic to Present at the BofA Securities 2020 Health Care Conference
- Morphic Therapeutic (MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that the Morphic executive team is scheduled to make a virtual presentation at the BofA Securities 2020 Health Care Conference at 3:00 p.m. ET on Wednesday, May 13, 2020. Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer.
- 04/29/2020
|
Biotech Roundup: GSK’s Ante, Shakeup at Sage, Telehealth’s Rise & More
- The COVID-19 pandemic has stopped enrollment in many clinical trials and postponed the start of others but there is still life in the life sciences
- 04/10/2020
|
Morphic (NASDAQ:MORF) Lifted to Buy at Zacks Investment Research
- Morphic (NASDAQ:MORF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Thursday, Zacks.com reports. The firm presently has a $15.00 price objective on the stock. Zacks Investment Research‘s target price suggests a potential upside of 9.49% from the stock’s previous close. According to Zacks, […]
- 04/09/2020
|
Analyzing Horizon Therapeutics (NASDAQ:HZNP) and Morphic (NASDAQ:MORF)
- Horizon Therapeutics (NASDAQ:HZNP) and Morphic (NASDAQ:MORF) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk. Institutional & Insider Ownership 89.7% of Horizon Therapeutics shares are owned by institutional investors. Comparatively, 45.9% of […]
- 04/08/2020
|
Morphic Announces Appointment of Marc Schegerin, M.D., as Chief Financial Officer and Chief Operating Officer
- Morphic Therapeutic (MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the appointment of Marc Schegerin, M.D., as chief financial officer and chief operating officer. Dr. Schegerin was most recently
- 04/07/2020
|
Bio Roundup: Coronavirus Diagnostics, Therapeutics, Vaccines & More
- The past week brought a sea change in many of our daily lives as the impact of the continued spread of the novel coronavirus altered how we work and play
- 03/20/2020
|
Morphic Announces Appointment of Peter G. Linde, M.D., as Chief Medical Officer
- Morphic Therapeutic (MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the appointment of Peter G. Linde, M.D., as chief medical officer. Dr. Linde was previously vice president of medical research at Acceleron Pharma, Inc., where he was responsible for the design and execution of clinical trials with positive outcomes in both pulmonary and hematologic diseases. Dr. Linde will oversee the development of Morphic’s small molecule integrin inhibitors as the company advances its oral integrin inhibitors toward clinical trials.
- 03/17/2020
|
Morphic Therapeutic to Present at the 40th Annual Cowen Health Care Conference
- WALTHAM, Mass., Feb. 28, 2020 -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the.
- 02/28/2020
|
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2019
- WALTHAM, Mass., Feb. 27, 2020 -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of.
- 02/27/2020
|
Morphic Presents Positive Preclinical Data Supporting MORF-057 as an Oral Inhibitor of the α4β7 Integrin and Potential Treatment for Inflammatory Bowel Disease
- Oral presentation at ECCO highlights MORF-057 as a potent, selective and orally available small molecule development candidate Mechanism of action demonstrated in in vitro.
- 02/14/2020
|
Morphic to Present at the 38th Annual J.P. Morgan Healthcare Conference
- WALTHAM, Mass., Jan. 08, 2020 -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of.
- 01/08/2020
|
Hedge Funds Are Dumping Morphic Holding, Inc. (MORF)
- It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. Since stock returns aren't usually symmetrically distributed and index […]
- 11/30/2019
|
Morphic to Present at the Jefferies 2019 London Healthcare Conference
- WALTHAM, Mass., Nov. 18, 2019 -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of.
- 11/18/2019
|
Morphic Announces Corporate Highlights and Third Quarter 2019 Financial Results
- MORF-720, αvβ6-targeted oral integrin inhibitor IND now anticipated in the second half of 2020α4β7-targeted oral integrin inhibitor candidate for IBD on track for IND by.
- 11/12/2019
|
Hedge Funds Have Never Been This Bullish On Morphic Holding, Inc. (MORF)
- We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Hedge funds' top 3 stock picks returned 34.4% this year and beat the S&P; […]
- 10/30/2019
|
Morphic to Present at the Wells Fargo Securities 2019 Healthcare Conference
- WALTHAM, Mass., Aug. 30, 2019 -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of.
- 08/30/2019
|
Morphic Announces Corporate Highlights and Second Quarter 2019 Financial Results
- - Successful IPO provides more than $100 million in gross proceeds to advance leading oral integrin development pipeline and MInT discovery platform - Company remains on track.
- 08/12/2019
|
The Daily Biotech Pulse: Verrica Rallies, Aclaris Flunked Hair Loss Study, 3 Biotechs To IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 26) Odonate Therapeutics Inc (NASDAQ: ODT ) Down In The ...
- 06/27/2019
|
Morphic Announces Pricing of Upsized Initial Public Offering
- Morphic Holding, Inc. (“Morphic”), a biopharmaceutical company discovering and developing oral small-molecule integrin therapeutics, today announced the pricing of its upsized initial public offering of 6,000,000 shares of its common stock at a price to the public of $15.00 per share. Jefferies LLC, Cowen and Company, LLC, BMO Capital Markets Corp. and Wells Fargo Securities, LLC are acting as joint book-running managers for the offering. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and became effective on June 26, 2019.
- 06/27/2019
|
